Secondary Trigeminal Neuralgia (Investigational Adjunct)
Highly investigational adjunct for secondary trigeminal neuralgia after MRI evaluation; carbamazepine and oxcarbazepine remain first-line; microvascular decompression for refractory cases.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for trigeminal neuralgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for secondary trigeminal neuralgia is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). Only case reports; there are no randomized controlled trials. Evidence-based therapy for trigeminal neuralgia: carbamazepine or oxcarbazepine as first-line (AAN-endorsed), with lamotrigine, baclofen, or gabapentin as alternatives. Microvascular decompression surgery in selected fit patients (long-term pain relief >70 percent). Gamma knife radiosurgery and percutaneous procedures (glycerol injection, balloon compression, radiofrequency thermocoagulation) for medically refractory disease. Secondary causes (multiple sclerosis, tumor) require treatment of the underlying disease.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Trigger of acute trigeminal pain attack at bite locations on the face
- Local skin infection or, rarely, Aeromonas infection on the face
- Allergic reaction to leech saliva (uncommon)
- Post-inflammatory hyperpigmentation or scarring on the face
- Risk if leech placed too close to the eye or ophthalmic branch
- Delay of carbamazepine, microvascular decompression, or workup for secondary causes
- Risk of missed multiple sclerosis or tumor as cause of secondary trigeminal neuralgia
- Quién no debería considerar esto
- Patients who have not been worked up for multiple sclerosis or tumor (MRI required)
- Patients with active herpes zoster of the trigeminal nerve
- Patients with eye involvement or first-division (V1) trigeminal pain (specialty care)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not tried carbamazepine or oxcarbazepine
- Patients with darker Fitzpatrick skin types at high PIH risk on the face
- Qué preguntar a su clínico
- Have I had an MRI brain to rule out multiple sclerosis or tumor?
- Have I tried carbamazepine or oxcarbazepine at therapeutic doses?
- Am I a candidate for microvascular decompression or gamma knife radiosurgery?
- What evidence specifically supports leech therapy for trigeminal neuralgia?
- What is the risk of triggering a pain attack with facial leech bites?
- Are leeches from an FDA-registered supplier and used only once?
- What is the cost and is it covered by insurance? (typically not covered)
- Cuándo buscar atención urgente
- New double vision, eye pain, or vision loss (cranial nerve or eye involvement)
- Sudden severe facial weakness or numbness (possible stroke or tumor progression)
- New limb weakness, balance problems, or vision changes (possible MS exacerbation)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Qué NO significa esto
- This is NOT FDA-cleared for trigeminal neuralgia.
- Case reports do NOT establish efficacy versus carbamazepine, microvascular decompression, or gamma knife radiosurgery.
- It does NOT replace MRI workup for secondary causes (MS, tumor) in secondary trigeminal neuralgia.
- It does NOT substitute for evidence-based pharmacologic or surgical therapy.
- It does NOT mean facial leech application is safe — pigment changes and scarring are facial-cosmetic concerns.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- neurological
- ICD-10
- G50.0
- Safety tier
- high
Evidence Summary
Trigeminal neuralgia (TN) involves paroxysmal lancinating facial pain in trigeminal distribution. Classical TN is often associated with neurovascular compression at the root entry zone; secondary TN may relate to multiple sclerosis or tumor. Per AAN and EFNS guidance, first-line therapy is carbamazepine or oxcarbazepine; surgical options for refractory cases include microvascular decompression, percutaneous procedures, and stereotactic radiosurgery. No controlled clinical trial of hirudotherapy for trigeminal neuralgia has been published; any use is investigational and mechanistic only. MRI evaluation must be completed before any adjunctive consideration.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Krashenyuk AI (2010)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- MRI not completed (intracranial mass or MS demyelination must be excluded)
- Facial placement directly on trigeminal distribution
- Placement over temporal artery (risk of arterial bleeding)
- Discontinuation of first-line pharmacotherapy
- Active dental or sinus pathology mimicking TN
Related Conditions
Cervical Radiculopathy
Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.
Lumbar Radiculopathy (Sciatica)
Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.
Migraine
Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.
Tension-Type Headache
Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.